New publication from the University of Stuttgart using Attana

The team of Professor Dr. Roland Kontermann at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany has recently published an article in PLOS ONE titled A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
Professor Kontermann's group is working on the development of novel strategies for tumor therapy. The strategies are based on the use of specific ligands to target potent cytotoxic effector mechanism to the tumor. Their focus is on three effector arms: 1) bispecific antibodies for the retargeting of effector cells of the immune system (immunotherapy), 2) targeted carrier systems (liposomes, polymers) for drug delivery (chemotherapy), and 3) targeted cytotoxic fusion proteins (biotherapy). Main targets are molecules associated with the tumor vasculature (vascular targeting), since these structures are easily accessible for circulating agents and all solid tumors are dependent on vascularisation.
In this publication the group employed their Attana A200 system for affinity determination.

Read more